I've been advising a Biotech/Biopharma company that has spent the last 5 years developing a groundbreaking and now patented drug delivery platform.

Two companies have sub-licensed the platform in the diabetes management and oncology spaces. Base on trials to date, both companies seem to have blockbuster potential,

Each is raising $7-$10M in Seed/Series A funding which will go to further testing on NHPs, building up the management team, starting fast-track FDA approval process and engaging a Big Pharma partner.

An early exit expectedredactedmonths). DM me for more details and to set up a chat.